Clinical trial
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837
Study timeline
Study start (actual)2024-02-19Date precision: day
Registry last updated2026-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
vepdegestrantDRUG · verified · RxNorm: vepdegestrant
PF-07220060DRUG
Sponsors & collaborators
Pfizerlead sponsor
Arvinas Estrogen Receptor, Inc.collaborator
Mapped research locations
New YorkNew York, United States3New HavenConnecticut, United States3Palo AltoCalifornia, United States3TorontoOntario, Canada2Salt Lake CityUtah, United States2IrvineCalifornia, United States2Fort CollinsColorado, United States2San AntonioTexas, United States1San FranciscoCalifornia, United States1GuangzhouGuangdong, China1SevilleSpain1OttawaOntario, Canada1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06206837 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.